The OMEGA-SPM-DOSE trial and the OMEGA-SPM-PAD trial are two parts of a pilot study which
aims to investigate the effect of a novel formulation of a nutritional supplement containing
highly concentrated n-3 PUFA metabolites (SPM Emulsion) on the metabolo-lipidomic profile of
healthy volunteers and patients with PAD. Ten healthy volunteers and ten patients with PAD
will participate in Part 1a, the "OMEGA-SPM-DOSE Study". A follow-up, placebo controlled,
prospective study on the best dosing modality determined in Phase 1a will then take place in
a wider PAD population (n=30), Phase 1b - the "OMEGA-SPM-PAD Study". Specific measurements
will include targeted metabolo-lipidomic profiling, established markers of inflammation, and
functional monocyte and macrophage assays. The proposed studies have the potential to provide
important new insights on the role of nutritional interventions in PAD.